Secretary for Health commences visit to Nanjing (with photos)
*************************************************************
During the meeting with the Commissioner of the Jiangsu Commission of Health, Ms Tan Ying, Professor Lo introduced the efforts of the Hong Kong Special Administrative Region (HKSAR) Government in promoting the international inheritance and innovation of Chinese medicine, as well as the high-quality development of public hospitals.
Professor Lo said, "The HKSAR Government is committed to developing Hong Kong into a bridgehead for the internationalisation of Chinese medicine and promoting the high-quality and high-standard development of Chinese medicine in Hong Kong on all fronts. Jiangsu and Hong Kong have established a solid foundation in Chinese medicine academic inheritance and talent exchange. By the end of this year, the two flagship projects, namely the Chinese Medicine Hospital of Hong Kong (CMHHK) and the permanent Government Chinese Medicines Testing Institute building, will commence services in phases. This will further strengthen the co-operation between the two places in the areas of Chinese medicine services, talent development and testing research."
Regarding the high-quality development of public hospitals, Professor Lo emphasised that the HKSAR Government will continue to promote the accreditation of more public hospitals under the China's International Hospital Accreditation Standards (2021 Version), with a view to maintaining the high standard of hospital management and services in the HKSAR while aligning with the national healthcare service system. Apart from Pamela Youde Nethersole Eastern Hospital and Prince of Wales Hospital, which have been successfully accredited in December last year and March this year respectively, the Hospital Authority will launch the accreditation programme at Queen Mary Hospital, United Christian Hospital and Tuen Mun Hospital this year, and plans to implement the programme at one major acute hospital under each of the seven hospital clusters by 2026. The participation of public hospitals in the relevant accreditation programme can serve as a demonstration to the international community of the national hospital accreditation standards, with Hong Kong acting as a gateway to facilitate the national standards going global. In this connection, both sides also explored ways to further encourage more hospitals in the two places to pursue accreditation under the relevant standards to amplify the impact of national standards.
Professor Lo also visited Simcere Pharmaceutical Group headquartered in Nanjing earlier. He introduced the senior management of the company to the initiatives put forward by the HKSAR Government in developing Hong Kong into an international health and medical innovation hub, including strengthening the approval regimes for drugs and medical devices, as well as promoting the development of the clinical trial industry.
He said, "The Chief Executive announced in his 2023 and 2024 Policy Addresses to develop Hong Kong into an international health and medical innovation hub. We will set up the Hong Kong Centre for Medical Products Regulation by the end of next year to accelerate the clinical use of new drugs and medical devices. Moreover, the HKSAR Government will make full use of the Greater Bay Area International Clinical Trial Institute located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone, and working in collaboration with the Greater Bay Area International Clinical Trials Center in the Shenzhen Park to jointly establish a one-stop clinical trial collaboration platform."
Professor Lo encouraged Mainland pharmaceutical companies to make good use of the "1+" mechanism and "primary evaluation" for new drug registration, which will be rolled out in phases starting next year, to introduce newly developed drugs into Hong Kong to meet local healthcare needs and access international markets through Hong Kong. He also welcomed Mainland pharmaceutical companies to conduct clinical trials in Hong Kong, fully leveraging the multiple unique advantages of the HKSAR to facilitate the translation and clinical application of advanced biomedical technologies.
Professor Lo will attend the 13th Nanjing Academic Symposium on Hepatobiliary Surgery and Liver Transplantation and visit a local hospital in Nanjing tomorrow.
Ends/Friday, July 11, 2025
Issued at HKT 19:00
Issued at HKT 19:00
NNNN
Photo
